WellSpring Pharmaceutical Corporation acquires BONINE®
WellSpring Pharmaceutical Corporation acquires BONINE®, an over-the-counter drug for motion sickness, from Prestige Brands Holdings, Inc.
WellSpring Pharmaceutical Corporation today announced its acquisition of BONINE®, an over-the-counter drug for motion sickness, from Prestige Brands Holdings, Inc.
The addition of BONINE® provides significant scale to its U.S.OTC nausea franchise. Its EMETROL® brand is the #1 pharmacist recommended nausea remedy, and has provided consumers with relief from nausea related to stomach flu and over-indulgence for over 50 years.
“To add a growing and innovative brand such as BONINE® provides us with the opportunity to offer a meaningful solution to help consumers prevent and treat nausea related to motion sickness. We look forward to helping people to better enjoy themselves and to be more productive, wherever their travels may take them,” said Rob Hasselman, Vice President of Sales and Marketing at WellSpring.
Founded in 1999, WellSpring Pharmaceutical Corporation is a privately held company which manufactures and markets a portfolio of well-recognized OTC brands that are widely distributed throughout the U.S. and Canada. Its prescription drug portfolio consists of brands that are recognized as highly effective therapies for certain niche patient populations. In addition, WellSpring is a contract manufacturing organization serving well-known U.S. pharmaceutical companies. Its wholly owned subsidiary operates an FDA and Health Canada inspected manufacturing plant in Oakville, Ontario, Canada. In October 2011, WellSpring was acquired by Sentinel and Ancor in partnership with its management team. For more information, visit www.wellspringpharm.com.